135 related articles for article (PubMed ID: 16219622)
1. Pharmacokinetics and efficacy of ifosfamide or trofosfamide in patients with intraocular lymphoma.
Jahnke K; Wagner T; Bechrakis NE; Willerding G; Coupland SE; Fischer L; Thiel E; Korfel A
Ann Oncol; 2005 Dec; 16(12):1974-8. PubMed ID: 16219622
[TBL] [Abstract][Full Text] [Related]
2. Ifosfamide or trofosfamide in patients with intraocular lymphoma.
Jahnke K; Thiel E; Bechrakis NE; Willerding G; Kraemer DF; Fischer L; Korfel A
J Neurooncol; 2009 Jun; 93(2):213-7. PubMed ID: 19099202
[TBL] [Abstract][Full Text] [Related]
3. New insights into the clinical pharmacokinetics of trofosfamide.
Brinker A; Kisro J; Letsch C; Brüggemann SK; Wagner T
Int J Clin Pharmacol Ther; 2002 Aug; 40(8):376-81. PubMed ID: 12467306
[TBL] [Abstract][Full Text] [Related]
4. Investigations on the pharmacokinetics of trofosfamide and its metabolites-first report of 4-hydroxy-trofosfamide kinetics in humans.
Preiss R; Baumann F; Stefanovic D; Niemeyer U; Pönisch W; Niederwieser D
Cancer Chemother Pharmacol; 2004 Jun; 53(6):496-502. PubMed ID: 15138712
[TBL] [Abstract][Full Text] [Related]
5. Intraocular lymphoma 2000-2005: results of a retrospective multicentre trial.
Jahnke K; Korfel A; Komm J; Bechrakis NE; Stein H; Thiel E; Coupland SE
Graefes Arch Clin Exp Ophthalmol; 2006 Jun; 244(6):663-9. PubMed ID: 16228920
[TBL] [Abstract][Full Text] [Related]
6. Trofosfamide metabolism in different species--ifosfamide is the predominant metabolite.
Boos J; Küpker F; Blaschke G; Jürgens H
Cancer Chemother Pharmacol; 1993; 33(1):71-6. PubMed ID: 8269592
[TBL] [Abstract][Full Text] [Related]
7. Metabolism of ifosfamide to chloroacetaldehyde contributes to antitumor activity in vivo.
Börner K; Kisro J; Brüggemann SK; Hagenah W; Peters SO; Wagner T
Drug Metab Dispos; 2000 May; 28(5):573-6. PubMed ID: 10772637
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of trofosfamide and its dechloroethylated metabolites.
Hempel G; Krümpelmann S; May-Manke A; Hohenlöchter B; Blaschke G; Jürgens H; Boos J
Cancer Chemother Pharmacol; 1997; 40(1):45-50. PubMed ID: 9137528
[TBL] [Abstract][Full Text] [Related]
9. Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics.
Boddy AV; English M; Pearson AD; Idle JR; Skinner R
Eur J Cancer; 1996 Jun; 32A(7):1179-84. PubMed ID: 8758250
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer.
Willits I; Price L; Parry A; Tilby MJ; Ford D; Cholerton S; Pearson AD; Boddy AV
Br J Cancer; 2005 May; 92(9):1626-35. PubMed ID: 15827549
[TBL] [Abstract][Full Text] [Related]
11. Penetration of ifosfamide and its active metabolite 4-OH-ifosfamide into cerebrospinal fluid of patients with CNS malignancies.
Kiewe P; Neumann M; Wagner T; Seyfert S; Albrecht H; Thiel E; Korfel A
Cancer Chemother Pharmacol; 2011 Jan; 67(1):27-33. PubMed ID: 20182727
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of ifosfamide and some metabolites in children.
Kaijser GP; De Kraker J; Bult A; Underberg WJ; Beijnen JH
Anticancer Res; 1998; 18(3B):1941-9. PubMed ID: 9677448
[TBL] [Abstract][Full Text] [Related]
13. Poly-isoprenylated ifosfamide analogs: Preactivated antitumor agents as free formulation or nanoassemblies.
Skarbek C; Delahousse J; Pioche-Durieu C; Baconnais S; Deroussent A; Renevret P; Rivard M; Desmaele D; Martens T; Le Cam E; Couvreur P; Paci A
Int J Pharm; 2017 Nov; 532(2):748-756. PubMed ID: 28546071
[TBL] [Abstract][Full Text] [Related]
14. Treatment of primary intraocular lymphoma with oral trofosfamide: report of two cases and review of the literature.
Jahnke K; Bechrakis NE; Coupland SE; Schmittel A; Foerster MH; Fischer L; Thiel E; Korfel A
Graefes Arch Clin Exp Ophthalmol; 2004 Sep; 242(9):771-6. PubMed ID: 15349786
[TBL] [Abstract][Full Text] [Related]
15. Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion.
Silies H; Blaschke G; Hohenlöchter B; Rossi R; Jürgens H; Boos J
Int J Clin Pharmacol Ther; 1998 May; 36(5):246-52. PubMed ID: 9629987
[TBL] [Abstract][Full Text] [Related]
16. Ifosfamide: pharmacokinetic properties for central nervous system metastasis prevention.
Lokiec F
Ann Oncol; 2006 May; 17 Suppl 4():iv33-6. PubMed ID: 16702183
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of ifosfamide, 2- and 3-dechloroethylifosfamide in plasma and urine of cancer patients treated with a 10-day continuous infusion of ifosfamide.
Kaijser GP; Keizer HJ; Beijnen JH; Bult A; Underberg WJ
Anticancer Res; 1996; 16(5B):3247-57. PubMed ID: 8920799
[TBL] [Abstract][Full Text] [Related]
18. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
19. Stem cell toxicity of oxazaphosphorine metabolites in comparison to their antileukemic activity.
Brueggemann SK; Schlenke P; Klich S; Deeken M; Peters SO; Wagner T
Biochem Pharmacol; 2002 Apr; 63(7):1337-41. PubMed ID: 11960610
[TBL] [Abstract][Full Text] [Related]
20. Phenobarbital administration does not affect high-dose ifosfamide pharmacokinetics in humans.
Lokiec F; Santoni J; Weill S; Tubiana-Hulin M
Anticancer Drugs; 1996 Nov; 7(8):893-6. PubMed ID: 8991196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]